



Press release from Emotra AB (publ)

Göteborg, March 7, 2014

Co-operation agreement with clinical centres from three countries

Emotra has signed co-operation agreement with clinical teams from three countries in Europe, with one clinic from Madrid in Spain, with one from Montpellier in Spain and further with one from Ranveil, Vorarlberg in Austria. These are the twelfth, thirteenth and fourteenth clinical centres that have signed agreements to participate in clinical multi-centre study for the purpose of evaluating the use of EDOR to assess potential suicide risks.

So far, fourteen clinics have signed co-operation agreements with Emotra. The Company aims to involve around 15 European clinical centres in the clinical trials of Emotra's testing method for an initial market introduction in the first quarter 2014. We expect these trials to continue over the next two years, and discussions and negotiations are ongoing with several clinics from different countries. For the purpose of preparing these clinical studies, applications to ethical committees as well as for CE certification are simultaneously being drafted.

At present, Emotra is in the middle of a very dynamic phase involving an increasing number of clinical centres. In order to minimise the financial risks, all work is carried out within a small organisation and as cost-effectively as possible. When international, scientific support for EDOR from these clinics has grown sufficiently strong, we will launch the method in Europe.

For further information, please contact:

Claes Holmberg, CEO

Telephone: +46 708 25 45 47

E-mail: claes@emotra.se

Lars-Håkan Thorell, Head of Research

Telephone: +46 733 95 31 20

E-mail: lars@emotra.se

Emotra AB is listed on AktieTorget, and the Company has developed a method – EDOR – of detecting depressed patients who are at risk of committing suicide. Altogether, more than 1,000 patients have been tested and followed up. EDOR has shown a reliability rate of up to 97%. In other words, Emotra's method can determine, with 97% certainty, if a person runs a significantly higher risk of suicide attempt, facilitating decisions about where special suicide prevention measures are needed. EDOR helps the right patients get the care they need.